10x Genomics partners with Fudan University Shanghai Cancer Center and Shanghai Precision Diagnostics to use the Xenium platform in a 24-month study analyzing tumor biopsies from 500 breast cancer patients. The goal is to identify biomarkers that predict how patients respond to neoadjuvant therapy, potentially guiding personalized treatment and improving outcomes. This research leverages advanced single-cell and spatial biology technologies to uncover tumor features conventional methods might miss, aiming to enhance diagnostic precision and cancer care. Findings could lead to new diagnostic tools and more effective therapies tailored to individual patients.
Shares of 10x Genomics Inc (TXG) are trading at USD 64.00 on Pluang, down 1.61% in the last day. The stock has a market cap of $8.57 billion and shows a typical hold time of 92 days among investors. These figures are current as of Nov 10, 2026 21:12 WIB.
